Cycloserine 250mg capsules
Requires a prescription from a doctor or prescriber
Antibiotic substance produced by Streptomyces garyphalus.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Cycloserine
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Cycloserine
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
4 branded products available
MHRA licensed products
View all licensed products for Cycloserine on the MHRA register
Cycloserine 250mg capsules
WHO defined daily dose (DDD)
750 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(3)
Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (TA249)
Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)
LipiFlow thermal pulsation treatment for dry eyes caused by blocked meibomian glands (MIB29)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 12 · Randomised trials: 16 · 1972–2026
Showing the 50 most relevant studies, sorted by most relevant.
Melissa M. Norberg, John H. Krystal, David F. Tolin
Biological Psychiatry, 2008
- Desensitization, Psychologic
- Implosive Therapy
- Anxiety Disorders
Adam J. Guastella, Rick Richardson, Peter F. Lovibond, et al.
Biological Psychiatry, 2008
- Desensitization, Psychologic
- Combined Modality Therapy
- Cycloserine
Rianne A. de Kleine, Gert‐Jan Hendriks, Wendy J.C. Kusters, et al.
Biological Psychiatry, 2012
- Antimetabolites
- Combined Modality Therapy
- Cycloserine
JoAnn Difede, Judith Cukor, Katarzyna Wyka, et al.
Neuropsychopharmacology, 2013
- Implosive Therapy
- Anger
- Chronic Disease
Sebastian Schade, Walter Paulus
The International Journal of Neuropsychopharmacology, 2015
- Mental Disorders
- Cycloserine
- Nervous System Diseases
Brett T. Litz, Kristalyn Salters‐Pedneault, Maria M. Steenkamp, et al.
Journal of Psychiatric Research, 2012
- Cycloserine
- Implosive Therapy
- Psychiatric Status Rating Scales
Uriel Heresco‐Levy, Genia Gelfin, Boaz Bloch, et al.
The International Journal of Neuropsychopharmacology, 2012
- Antidepressive Agents
- Cycloserine
- Depressive Disorder, Major
David Mataix‐Cols, Lorena Fernández de la Cruz, Benedetta Monzani, et al.
JAMA Psychiatry, 2017
- Antidepressive Agents
- Anxiety Disorders
- Combined Modality Therapy
Adam J. Guastella, Mark R. Dadds, Peter F. Lovibond, et al.
Journal of Psychiatric Research, 2006
- Fear
- Combined Modality Therapy
- Cycloserine
Helga Rodrigues, Ivan Figueira, Alessandra Pereira Lopes, et al.
PLoS ONE, 2014
- Antimetabolites
- Anxiety Disorders
- Cycloserine
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
10 hours
Mechanism
Cycloserine is an analog of the amino acid D-alanine.
Food interactions
1 warning
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
70 to 90%
Half-life
10 hours
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 200 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
PMID:21376300 PMID:26875626 PMID:26919761 PMID:28126851 PMID:28228639 PMID:36959261 PMID:7679115 PMID:7681588 PMID:7685113
NMDARs participate in synaptic plasticity for learning and memory formation by contributing to the long-term potentiation (LTP) .
PMID:26875626
Channel activation requires binding of the neurotransmitter L-glutamate to the GluN2 subunit, glycine or D-serine binding to the GluN1 subunit, plus membrane depolarization to eliminate channel inhibition by Mg(2+) .
PMID:21376300 PMID:26875626 PMID:26919761 PMID:27164704 PMID:28095420 PMID:28105280 PMID:28126851 PMID:28228639 PMID:36959261 PMID:38538865 PMID:7679115 PMID:7681588 PMID:7685113
NMDARs mediate simultaneously the potasium efflux and the influx of calcium and sodium (By similarity). Each GluN2 or GluN3 subunit confers differential attributes to channel properties, including activation, deactivation and desensitization kinetics, pH sensitivity, Ca2(+) permeability, and binding to allosteric modulators PMID:26875626 PMID:26919761 PMID:36309015 PMID:38598639
Enzymes involved in drug metabolism — important for understanding drug interactions
Proteins that transport this drug across cell membranes
ATC J04AB01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Cycloserine
Additional database identifiers
Drugs Product Database (DPD)
8528
ChemSpider
5998
BindingDB
50038178
PDB
4AX
ZINC
ZINC000034676245
GenBank Gene Database
M58467
GenBank Protein Database
145722
UniProt Accession
DDLA_ECOLI
GenBank Gene Database
AF214487
GenBank Protein Database
6708455
UniProt Accession
ALR_MYCAV
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4584
GenAtlas
GRIN1
GeneCards
GRIN1
GenBank Gene Database
D13515
GenBank Protein Database
219920
Guide to Pharmacology
455
UniProt Accession
NMDZ1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2719
GenAtlas
DDC
GeneCards
DDC
GenBank Gene Database
M76180
GenBank Protein Database
181521
UniProt Accession
DDC_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:18762
GeneCards
SLC36A2
Guide to Pharmacology
1162
UniProt Accession
S36A2_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q418508), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.